To clarify the mechanisms of diarrheal disease induced by Aeromonas sobria, we examined whether prostaglandin E 2 (PGE 2 ) was involved in the intestinal secretory action of A. sobria hemolysin by use of a mouse intestinal loop model. The amount of PGE 2 in jejunal fluid and the fluid accumulation ratio were directly related to the dose of hemolysin. The increase over time in the level of PGE 2 was similar to that of the accumulated fluid. In addition, hemolysin-induced fluid secretion and PGE 2 synthesis were inhibited by the selective cyclooxygenase 2 (COX-2) inhibitor NS-398 but not the COX-1 inhibitor SC-560. Western blot analysis revealed that hemolysin increased the COX-2 protein levels but reduced the COX-1 protein levels in mouse intestinal mucosa in vivo. These results suggest that PGE 2 functions as an important mediator of diarrhea caused by hemolysin and that PGE 2 is produced primarily through a COX-2-dependent mechanism. Subsequently, we examined the relationship between PGE 2 , cyclic AMP (cAMP), and cystic fibrosis transmembrane conductance regulator (CFTR) Cl ؊ channels in mouse intestinal mucosa exposed to hemolysin. Hemolysin increased the levels of cAMP in the intestinal mucosa. NS-398 inhibited the increase in cAMP production, but SC-560 did not. In addition, H-89, a cAMP-dependent protein kinase A (PKA) inhibitor, and glibenclamide, a CFTR inhibitor, inhibited fluid accumulation. Taken together, these results indicate that hemolysin activates PGE 2 production via COX-2 and that PGE 2 stimulates cAMP production. cAMP then activates PKA, which in turn stimulates CFTR Cl ؊ channels and finally leads to fluid accumulation in the intestines.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.